Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant immune checkpoint inhibition and novel immuno-oncology combinations in early-stage colon cancer
2016-002940-17Phase 2Active
- Sponsor
- Netherlands Cancer Institute
- Start
- Sep 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of nivolumab, ipilimumab, adakitug and relatlimab in colon adenocarcinoma and colon cancer (4 cohorts), sponsored by Netherlands Cancer Institute. Primary endpoints: Safety in MSS cohort and Feasibility. Started Sep 2016; status: active.
02
Drugs
03
Conditions
colon adenocarcinomacolon cancer
Beyond the preview
Go deeper on 2016-002940-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002940-17.